Biohaven Pharmaceutical (NYSE:BHVN) insider Robert Berman sold 35,000 shares of the firm’s stock in a transaction on Tuesday, April 10th. The shares were sold at an average price of $24.66, for a total transaction of $863,100.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Robert Berman also recently made the following trade(s):
- On Monday, March 12th, Robert Berman sold 35,000 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $30.11, for a total transaction of $1,053,850.00.
- On Monday, February 12th, Robert Berman sold 35,000 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $30.42, for a total transaction of $1,064,700.00.
BHVN stock traded up $2.13 during trading hours on Thursday, reaching $27.43. The stock had a trading volume of 546,235 shares, compared to its average volume of 765,025. The stock has a market cap of $925.65 and a P/E ratio of -5.49. Biohaven Pharmaceutical has a fifty-two week low of $16.50 and a fifty-two week high of $39.51.
Biohaven Pharmaceutical (NYSE:BHVN) last announced its quarterly earnings results on Tuesday, March 6th. The company reported ($0.75) EPS for the quarter, beating analysts’ consensus estimates of ($1.33) by $0.58. research analysts expect that Biohaven Pharmaceutical will post -4.27 EPS for the current fiscal year.
A number of research analysts recently weighed in on the stock. Barclays downgraded shares of Biohaven Pharmaceutical from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $30.00 to $25.00 in a research report on Thursday, April 5th. Piper Jaffray reaffirmed a “buy” rating on shares of Biohaven Pharmaceutical in a research report on Monday, March 26th. Canaccord Genuity reaffirmed a “buy” rating and issued a $34.00 target price (down previously from $39.00) on shares of Biohaven Pharmaceutical in a research report on Monday, March 26th. Zacks Investment Research raised shares of Biohaven Pharmaceutical from a “hold” rating to a “buy” rating and set a $33.00 target price for the company in a research report on Friday, March 9th. Finally, Needham & Company LLC reaffirmed a “buy” rating on shares of Biohaven Pharmaceutical in a research report on Thursday, February 22nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $37.14.
Hedge funds have recently made changes to their positions in the business. Legal & General Group Plc acquired a new stake in Biohaven Pharmaceutical in the third quarter valued at $119,000. Nationwide Fund Advisors acquired a new stake in Biohaven Pharmaceutical in the third quarter valued at $214,000. American International Group Inc. acquired a new stake in Biohaven Pharmaceutical in the third quarter valued at $251,000. Susquehanna International Group LLP acquired a new stake in Biohaven Pharmaceutical in the third quarter valued at $302,000. Finally, Endurant Capital Management LP acquired a new stake in Biohaven Pharmaceutical in the fourth quarter valued at $278,000. Hedge funds and other institutional investors own 61.84% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Insider Selling: Biohaven Pharmaceutical (BHVN) Insider Sells 35,000 Shares of Stock” was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://ledgergazette.com/2018/04/12/insider-selling-biohaven-pharmaceutical-bhvn-insider-sells-35000-shares-of-stock.html.
About Biohaven Pharmaceutical
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases.
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.